Adeno-associated virus-mediated gene transfer

Journal of Cellular Biochemistry

Volumn 105, Issue 1, 2008, Pages 17-24

  Srivastava, Arun ^a,b,c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Cancer and Genetics Research Complex   (United States)

Author keywords

Adeno associated virus; Gene expression; Gene transfer; Hematopoietic stem cells; Viral vectors

Indexed keywords

DNA; ENHANCED GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; BONE MARROW TRANSPLANTATION; GENE TRANSFER; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SEROTYPE; SOUTHERN BLOTTING; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS GENOME; VIRUS MUTANT; VIRUS RECOMBINANT;

ANIMALS; DEPENDOVIRUS; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HUMANS; TRANSGENES;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS - 2; ANIMALIA; MIRIDAE; MURINAE;

EID: 51849168557     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21819     Document Type: Review

References (51)

1. Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR, McNamara SC, Gibson RL, Ramsey BW, Carter BJ, Reynolds TC. 2001. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther 12:1907-1916.
2. Alexander IE, Russell DW, Miller AD. 1997. Transfer of contaminants in adeno-associated virus vector stocks can mimic transduction and lead to artifactual results. Hum Gene Ther 8:1911-1920.
3. Asokan A, Samulski RJ. 2005. From crystal structure to clinic: Highlights of the Tenth International Parvovirus Workshop. Mol Ther 11:656-660.
4. Bell P, Wang L, Lebherz C, Flieder DB, Bove MS, Wu D, Gao GP, Wilson JM, Wivel NA. 2005. No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. Mol Ther 12:299-306.
5. Bell P, Moscioni AD, McCarter RJ, Wu D, Gao G, Hoang A, Sanmiguel JC, Sun X, Wivel NA, Raper SE, Furth EE, Batshaw ML, Wilson JM. 2006. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther 14:34-44.
6. Berns KI, Bohenzky RA. 1987. Adeno-associated viruses: An update. Adv Virus Res 32:243-306.
7. Cordier L, Gao GP, Hack AA, McNally EM, Wilson JM, Chirmule N, Sweeney HL. 2001. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther 12:205-215.
8. Deichmann A, Hacein-Bey-Abina S, Schmidt M, Garrigue A, Brugman MH, Hu J, Glimm H, Gyapay G, Prum B, Fraser CC, Fischer N, Schwarzwaelder K, Siegler ML, de Ridder D, Pike-Overzet K, Howe SJ, Thrasher AJ, Wagemaker G, Abel U, Staal FJ, Delabesse E, Villeval JL, Aronow B, Hue C, Prinz C, Wissler M, Klanke C, Weissenbach J, Alexander I, Fischer A, von Kalle C, Cavazzana-Calvo M. 2007. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 117:2225-2232.
9. Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW, Sands MS. 2007. AAV vector integration sites in mouse hepatocellular carcinoma. Science 317:477.
10. Duan D, Sharma P, Yang J, Yue Y, Dudus L, Zhang Y, Fisher KJ, Engelhardt JF. 1998. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 72:8568-8577.
11. Edelstein ML, Abedi MR, Wixon J. 2007. Gene therapy clinical trials worldwide to 2007 - An update. J Gene Med 9:833-842.
12. Flotte T, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B, Taylor G, Walden S, Wetzel R. 1996. A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 7:1145-1159.
13. Flotte TR, Brantly ML, Spencer LT, Byrne BJ, Spencer CT, Baker DJ, Humphries M. 2004. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum Gene Ther 15:93-128.
14. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99:11854-11859.
15. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM. 2004. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 78:6381-6388.
16. Griffey MA, Wozniak D, Wong M, Bible E, Johnson K, Rothman SM, Wentz AE, Cooper JD, Sands MS. 2006. CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Mol Ther 13:538-547.
17. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M. 2003. LM02-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415-419.
18. Han Z, Zhong L, Maina N, Hu Z, Li X, Chouthai NS, Bischof D, Weigel-Van Aken KA, Slayton WB, Yoder MC, Srivastava A. 2008. Recombinant AAV proviral genomes are stably integrated in primary murine hematopoietic stem cells. Hum Gene Ther 19:267-278.
19. Hargrove PW, Vanin EF, Kurtzman GJ, Nienhuis AW. 1997. High-level globin gene expression mediated by a recombinant adeno-associated virus genome that contains the 3′ gamma globin gene regulatory element and integrates as tandem copies in erythroid cells. Blood 89:2167-2175.
20. Hermonat PL, Muzyczka N. 1984. Use of adeno-associated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA 81:6466-6470.
21. Inagaki K, Ma C, Storm TA, Kay MA, Nakai H. 2007. The role of DNA-PKcs and Artemis in opening viral DNA hairpin termini in various tissues in mice. J Virol 81:11304-11321.
22. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA. 2000. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24:257-261.
23. Kohn DB, Sadelain M, Dunbar C, Bodine D, Kiem HP, Candotti F, Tisdale J, Riviere I, Blau CA, Richard RE, Sorrentino B, Nolta J, Malech H, Brenner M, Cornetta K, Cavagnaro J, High K, Glorioso J. 2003. American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther 8:180-187.
24. LaFace D, Hermonat P, Wakeland E, Peck A. 1988. Gene transfer into hematopoietic progenitor cells mediated by an adeno-associated virus vector. Virology 162:483-486.
25. Li C, Bowles DE, van Dyke T, Samulski RJ. 2005. Adeno-associated virus vectors: Potential applications for cancer gene therapy. Cancer Gene Ther 12:913-925.
26. Maina N, Han Z, Zhao W, Li X, Hu Z, Zhong L, Bischof D, Weigel-Van Aken KA, Slayton WB, Yoder MC, Srivastava A. 2008. Recombinant scAAV serotype vector-mediated transduction of hematopoietic stem cells and lineage-restricted long-term transgene expression in progenitor cells in a murine serial bone marrow transplantation model. Hum Gene Ther 19:376-383.
27. Malik P, McQuiston SA, Yu XJ, Pepper KA, Krall WJ, Podsakoff GM, Kurtzman GJ, Kohn DB. 1997. Recombinant adeno-associated virus mediates a high level of gene transfer but less efficient integration in the K562 human hematopoietic cell line. J Virol 71:1776-1783.
28. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, Tai SJ, Ragni MV, Thompson A, Ozelo M, Couto LB, Leonard DG, Johnson FA, McClelland A, Scallan C, Skarsgard E, Flake AW, Kay MA, High KA, Glader B. 2003. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101:2963-2972.
29. McCown TJ, Xiao X, Li J, Breese GR, Samulski RJ. 1996. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res 713:99-107.
30. Muzyczka N, Samulski RJ, Hermonat P, Srivastava A, Berns KI. 1984. The genetics of adeno-associated virus. Adv Exp Med Biol 179:151-161.
31. Nakai H, Montini E, Fuess S, Storm TA, Grompe M, Kay MA. 2003. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet 34:297-302.
32. Nathwani AC, Hanawa H, Vandergriff J, Kelly P, Vanin EF, Nienhuis AW. 2000. Efficient gene transfer into human cord blood CD34+ cells and the CD34+ CD38- subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV. Gene Ther 7:183-195.
33. Paz H, Wong CA, Li W, Santat L, Wong KK, Chatterjee S. 2007. Quiescent subpopulations of human CD34-positive hematopoietic stem cells are preferred targets for stable recombinant adeno-associated virus type 2 transduction. Hum Gene Ther 18:614-626.
34. Ponnazhagan S, Mukherjee P, Wang XS, Qing K, Kube DM, Mah C, Kurpad C, Yoder MC, Srour EF, Srivastava A. 1997. Adeno-associated virus type 2-mediated transduction in primary human bone marrow-derived CD344+ hematopoietic progenitor cells: Donor variation and correlation of transgene expression with cellular differentiation. J Virol 71:8262-8267.
35. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML. 2003. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80:148-158.
36. Rolling F, Le Meur G, Stieger K, Smith AJ, Weber M, Deschamps JY, Nivard D, Mendes-Madeira A, Provost N, Pereon Y, Cherel Y, Ali RR, Hamel C, Moullier P, Rolling F. 2006. Gene therapeutic prospects in early onset of severe retinal dystrophy: Restoration of vision in RPE65 Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Bull Mem Acad R Med Belg 161:497-508; discussion 508-509.
37. Santat L, Paz H, Wong C, Li L, Macer J, Forman S, Wong KK, Chatteyee S. 2005. Recombinant AAV2 transduction of primitive human hematopoietic stem cells capable of serial engraftment in immune-deficient mice. Proc Natl Acad Sci USA 102:11053-11058.
38. Schuettrumpf J, Baila S, Khazi F, Liu J, Bunte R, Arruda VR. 2007. AAV vectors do not increase the risk of tumor formation in p53 deficient models. Mol Ther 15(Suppl 1):S1.
39. Snyder RO, Francis J. 2005. Adeno-associated viral vectors for clinical gene transfer studies. Curr Gene Ther 5:3 11-321.
40. Srivastava A. 2001. Gene therapy with viral vectors: The hope, the problems, and the solution. J Hematother Stem Cell Res 10:321-322.
41. Srivastava A. 2004. Gene delivery to human and murine primitive hematopoietic stem and progenitor cells by AAV2 vectors. Methods Mol Biol 246:245-254.
42. Srivastava A. 2005. Hematopoietic stem cell transduction by recombinant adeno-associated virus vectors: Problems and solutions. Hum Gene Ther 16:792-798.
43. Tan M, Qing K, Zhou S, Yoder MC, Srivastava A. 2001. Adeno-associated virus 2-mediated transduction and erythroid lineage-restricted long-term expression of the human beta-globin gene in hematopoietic cells from homozygous beta-thalassemic mice. Mol Ther 3:940-946.
44. Wagner JA, Nepomuceno IB, Messner AH, Mo ran ML, Batson EP, Dimiceli S, Brown BW, Desch JK, Norbash AM, Conrad CK, Guggino WB, Flotte TR, Wine JJ, Carter BJ, Reynolds TC, Moss RB, Gardner P. 2002. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther 13:1349-1359.
45. Wu J, Zhao W, Zhong L, Han Z, Li B, Ma W, Weigel-Kelley KA, Warrington KH, Srivastava A. 2007. Self-complementary recombinant adeno-associated viral vectors: Packaging capacity and the role of rep proteins in vector purity. Hum Gene Ther 18:171-182.
46. Zhao W, Wu J, Zhong L, Srivastava A. 2007. Adeno-associated virus 2-mediated gene transfer: Role of a cellular serine/threonine protein phosphatase in augmenting transduction efficiency. Gene Ther 14:545-550.
47. Zhong L, Li W, Yang Z, Qing K, Tan M, Hansen J, Li Y, Chen L, Chan RJ, Bischof D, Maina N, Weigel-Kelley KA, Zhao W, Larsen SH, Yoder MC, Shou W, Srivastava A. 2004. Impaired nuclear transport and uncoating limit recombinant adeno-associated virus 2 vector-mediated transduction of primary murine hematopoietic cells. Hum Gene Ther 15:1207-1218.
48. Zhong L, Li W, Li Y, Zhao W, Wu J, Li B, Maina N, Bischof D, Qing K, Weigel-Kelley KA, Zolotukhin I, Warrington KH, Jr., Li X, Slayton WB, Yoder MC, Srivastava A. 2006a. Evaluation of primitive murine hematopoietic stem and progenitor cell transduction in vitro and in vivo by recombinant adeno-associated virus vector serotypes 1 through 5. Hum Gene Ther 17:321-333.
49. Zhong L, Zhao W, Wu J, Maina N, Han Z, Srivastava A. 2006b. Adeno-associated virus-mediated gene transfer in hematopoietic stem/ progenitor cells as a therapeutic tool. Curr Gene Ther 6:683-698.
50. Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper MA, Herzog RW, Zolotukhin I, Warrington KH, Jr., Weigel-Van Aken KA, Hobbs JA, Zolotukhin S, Muzyczka N, Srivastava A. 2008. Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at reduced doses. Proc Natl Acad Sci USA (in press).
51. Zhou SZ, Cooper S, Kang LY, Ruggieri L, Heimfeld S, Srivastava A, Broxmeyer HE. 1994. Adeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood. J Exp Med 179:1867-1875.